Home / Compounds / Orforglipron
Orforglipron
Non-peptide GLP-1 receptor agonist · Foundayo in the United States. No UK brand name yet
- UK status
- Not licensed in the UK
- Availability
- Not available in the UK
- Evidence base
- Human RCT, phase 3
- Controlled drug
- No
Sequence
Not a peptide. A small molecule, so there is no amino acid sequence.
The short version
What it does
Reduces appetite, like the GLP-1 injections, but as a tablet you can take any time with or without food.
How it does it
Copying a gut hormone means building something your stomach destroys, which is why those drugs are injected. This is an ordinary drug molecule instead, designed to press the same button, and it survives being swallowed.
The catch
You cannot get it in the UK. It is approved in America and still under review here. Anyone selling it to you now is breaking the law and you have no idea what is in the packet.
Everything below goes into the detail, with sources.
Orforglipron matters for one structural reason: it does the same job as the GLP-1 injections but it is not built from amino acids. That single difference is why it can be swallowed.
At a glance
- Compound type
- Small molecule. Not a peptide.
- Drug class
- Non-peptide GLP-1 receptor agonist
- Route
- Tablet
- Frequency
- Daily, with or without food
- Originator
- Eli Lilly
- US approval
- 1 April 2026, as Foundayo
- UK status
- Under MHRA review. Not available.
- In sport
- Not currently on the WADA Prohibited List. Verify with UKAD.
01What it is
Every GLP-1 drug before it was a peptide, and peptides are destroyed by the digestive system. That is why Wegovy and Mounjaro are injections. Oral semaglutide gets around the problem with an absorption enhancer and strict rules about taking it on an empty stomach.
Orforglipron takes a different route. It is a small molecule, conventional drug chemistry rather than a copy of a hormone, designed to activate the same GLP-1 receptor. Being a small molecule means it survives the stomach on its own, needs no food or water restrictions, and is far easier to manufacture at scale.
Because it is the clearest illustration of what the word peptide does and does not tell you. Orforglipron is not a peptide but does the same thing as one. BPC-157 is a peptide and does nothing that has been demonstrated in humans. Structure is not function.
02How it came about
The oral GLP-1 problem is old and specific. Peptides are digested, so every GLP-1 drug until recently had to be injected. Oral semaglutide got round it with an absorption enhancer and strict fasting rules, which works but constrains how you take it.
Orforglipron attacks the problem from the other end: rather than protecting a peptide, build a conventional small molecule that happens to fit the same receptor. That took years of medicinal chemistry, because the GLP-1 receptor is large and was long considered a poor target for small molecules. The FDA approved it in April 2026.
03UK legal and licensing status
Orforglipron has no MHRA marketing authorisation. It cannot be lawfully prescribed or supplied in the UK, on the NHS or privately. Any UK-facing site offering it is operating outside the law, and because the Yellow Card scheme covers licensed medicines, a safety problem arising from an unlicensed import would not be captured by it.
The FDA approved it on 1 April 2026 in the United States, marketed as Foundayo. The manufacturer has submitted it for approval in a large number of countries including the UK. Public expectations put a UK decision around late 2026 or into 2027, with any NHS availability following a separate NICE appraisal after that.
Timelines from company statements and press coverage are estimates, not commitments. Check the MHRA for the actual decision rather than relying on any predicted date, including this one.
04How it works
It binds and activates the GLP-1 receptor, producing the same three effects as the injectable GLP-1 drugs.
- Glucose-dependent insulin release. More insulin when blood glucose is raised.
- Slower gastric emptying. Fullness lasts longer after eating.
- Reduced appetite signalling. Acting on the brain rather than the gut.
- Once daily, any time. No fasting window, unlike oral semaglutide. In practical terms this is the main advantage people care about.
05What it is not
Claims that attach themselves to this compound and do not hold up.
- Not a peptide, despite doing a peptide's job. The best illustration on this site that structure and function are different questions.
- Not available in the UK. No MHRA authorisation. Anything sold here as orforglipron is unlawful and unverifiable.
- Not the strongest option. On published figures it produces less weight change than tirzepatide at top dose. Its case is access and convenience.
- Not the same as the Wegovy tablet. Different companies, different chemistry. Oral semaglutide is a peptide with an absorption enhancer and needs an empty stomach. This does not.
06What the evidence shows
Phase 3 results reported average weight reduction in the region of 11 to 12 per cent of body weight over 72 weeks at the highest dose studied. Reported side effects followed the class pattern and were described as mostly mild to moderate and gastrointestinal.
Worth being precise about the comparison, because it is routinely overstated in both directions. On the published figures orforglipron produces less weight change than tirzepatide at its top dose, and roughly comparable or slightly more than oral semaglutide. The case for it is access, convenience and manufacturing scale, not maximum effect.
The ATTAIN-MAINTAIN trial, published in Nature Medicine in 2026, looked at whether weight reduction is maintained when people switch from an injectable GLP-1 to orforglipron.
No UK regulatory assessment has happened, so there is no SPC, no MHRA-approved patient information and no NICE view. Long-term data is still accumulating, as with everything in this class.
07Reported harms
Trial reporting describes the familiar gastrointestinal pattern: nausea, vomiting, diarrhoea and constipation. Because there is no UK licence there is no Summary of Product Characteristics, and therefore no authoritative frequency table for a UK reader.
The class-wide practical points still apply and are worth raising with a prescriber if it is ever licensed here: additional contraception alongside the oral contraceptive pill, and telling the anaesthetist before any procedure.
08Interactions and cautions
No UK prescribing information exists yet, so there is no authoritative interaction list for a UK reader. Trial-stage guidance has included backup contraception around starting and dose changes, and the class-wide surgery caution would be expected to apply.
Treat anything specific you read about interactions as provisional until an SPC exists.
09Stopping
No reason to expect it differs from the rest of the class: appetite suppression ends when the drug does. The ATTAIN-MAINTAIN trial looked at maintenance of weight reduction, including in people switching from injectables, which is the closest published evidence.
10Monitoring
Not applicable in the UK yet. There is no licence, no approved patient information, and no NICE view, so no UK monitoring framework exists.
11Questions worth asking
Take these to a doctor or pharmacist. A good clinician will not mind being asked, and the answers are specific to you in a way nothing on this page can be.
- Is there any lawful way for me to access this in the UK right now? (The answer is a clinical trial or nothing.)
- If I am waiting for it, is a licensed option sensible in the meantime?
- If I am already on an injectable, is there any reason to switch when this arrives?
12Common questions
Can I buy orforglipron in the UK?
No. It has no MHRA authorisation, so no UK pharmacy can lawfully supply it. Any site offering it is operating outside the law, and because the Yellow Card scheme covers licensed medicines, harm from an unlicensed import would not be captured.
When will it be available here?
Public expectations point to late 2026 or into 2027 for a private launch following MHRA approval, with NHS availability later still after a NICE appraisal. Those are estimates from company statements, not commitments.
Is a pill as good as the injections?
On weight reduction, less than tirzepatide at top dose and broadly comparable to oral semaglutide. The advantage is no needle, no fasting window, and easier manufacturing at scale, which matters for access rather than maximum effect.
Why is a non-peptide drug on a peptide reference site?
Because it does the same thing as the peptides and gets discussed alongside them, and because the contrast makes the point that the word peptide describes structure, not what something does or whether it works.
13Sources
Links go to the authoritative source. Where a document sits behind a paywall or moves around, the full citation is given so you can find it yourself.
- First GLP-1 tablet for weight loss approved in the UKMHRA, June 2026, for context on the oral class
- Orforglipron for maintenance of body weight reduction, ATTAIN-MAINTAINNature Medicine, 2026
- Phase 3 trial recordsClinicalTrials.gov
- Buying medicines onlineMHRA
- Technology appraisalsNICE
Get told when something changes
A short email when a licence changes, a safety alert lands, or a trial reports. No selling, no advertising, no sharing your address. Unsubscribe whenever.
14Change history
Every substantive change to this record is logged here with its date. Corrections are made openly, not quietly.
Loading…
Want telling when this record changes? Follow it from your account.